Kory Wentworth
About Kory Wentworth
Kory Wentworth is Chief Financial Officer and Treasurer of Entrada Therapeutics (TRDA), serving since November 2020; age 46 as of April 14, 2025. He previously held finance leadership roles at bluebird bio (VP of Finance, Dec 2017–Oct 2020), Alexion Pharmaceuticals (Executive Director & Corporate Controller, Dec 2008–Dec 2017), and was an Audit Manager at PwC (Oct 2002–Dec 2008). He holds a B.S. in Accounting from Susquehanna University and is a licensed CPA . Company performance during his tenure includes revenue scaling and a shift to positive EBITDA and net income by FY 2024 (see Performance table; values from S&P Global).*
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Entrada Therapeutics | Chief Financial Officer & Treasurer | Nov 2020–present | Senior finance leadership overseeing accounting, tax, treasury, operations, reporting . |
| bluebird bio | Vice President of Finance | Dec 2017–Oct 2020 | Led accounting, tax, treasury, finance operations and reporting; built global finance team . |
| Alexion Pharmaceuticals | Executive Director & Corporate Controller | Dec 2008–Dec 2017 | Oversaw finance and accounting teams; corporate controllership . |
| PricewaterhouseCoopers (PwC) | Audit Manager | Oct 2002–Dec 2008 | Assurance and business advisory; audit leadership . |
External Roles
No public company board or external director roles disclosed in TRDA proxy biographies for Wentworth .
Fixed Compensation
Wentworth was not listed as a Named Executive Officer (NEO) in the 2023 or 2024 compensation tables; detailed salary, target bonus %, and cash compensation disclosures for the CFO are not provided in the latest DEF 14A filings . As a result, base salary, target bonus %, and actual bonus paid for Wentworth are not disclosed and cannot be evaluated.
Performance Compensation
Performance-linked equity and bonus plan specifics for Wentworth are not individually disclosed. TRDA’s Senior Executive Cash Incentive Bonus Plan governs NEO annual bonuses using corporate/operational metrics that may include R&D milestones, EBITDA, net income, stock price changes, revenue, cash flow, returns on capital, and other measures; target bonus opportunities are set by the Compensation Committee but CF0-specific targets/weightings are not provided in the proxy . Equity award timing policies avoid grants around material nonpublic information and use pre-determined schedules .
Equity Ownership & Alignment
| Metric | Apr 5, 2022 | Apr 11, 2023 | Apr 16, 2024 | Apr 14, 2025 |
|---|---|---|---|---|
| Shares Beneficially Owned | 222,248 | 236,104 | 253,157 | 316,249 |
| Shares Outstanding (reference date) | 31,364,089 | 33,187,199 | 33,677,918 | 37,953,417 |
| Ownership % | 0.71% | 0.71% | 0.75% | 0.83% |
| Pledging/Hedging | Hedging and derivative transactions prohibited by insider trading policy; policy discusses risks of pledged/margin securities (no explicit pledging ban disclosed) | |||
| Rule 10b5-1 | Company permits compliant Rule 10b5-1 plans for officers/directors | |||
| Clawback | Compensation recovery policy adopted Sept 14, 2023 for financial restatements over prior 3 years |
Notes:
- Ownership % calculated using beneficial shares divided by total outstanding shares at each reference date (both cited above).
- No breakdown of vested vs. unvested RSUs/options or exercisable vs. unexercisable options is disclosed for Wentworth.
Employment Terms
- Role and tenure: CFO & Treasurer since November 2020; age 46 as of April 14, 2025 .
- Executive trading policies: Hedging and derivative transactions prohibited; Rule 10b5-1 plan policy in place .
- Clawback: Board-adopted compensation recovery policy in September 2023 compliant with SEC/Nasdaq rules .
- CFO-specific employment agreement terms (severance, change-of-control triggers, non-compete/non-solicit) are not disclosed in the proxies reviewed; similar terms are detailed for other executives (CEO/President/R&D), but not for Wentworth .
Company Performance During Wentworth’s Tenure
| Metric (USD) | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|
| Revenues | —* | —* | $129,013,000* | $210,782,000* |
| EBITDA | $(50,010,000)* | $(95,353,000)* | $(321,000)* | $50,784,000* |
| Net Income | $(51,158,000)* | $(94,616,000)* | $(6,685,000)* | $65,626,000* |
| Cash from Operations | $(50,862,000)* | $(93,786,000)* | $139,803,000* | $(41,557,000)* |
Notes:
- FY periods reflect TRDA reported fiscal years.
- Values retrieved from S&P Global.*
Investment Implications
- Alignment: Wentworth’s beneficial ownership has increased over time to ~0.83% of shares outstanding by April 2025, providing moderate alignment; prohibition on hedging/derivatives reduces misalignment risk, and 10b5-1 plans can structure orderly sales .
- Compensation transparency: Lack of CFO-specific compensation and severance/CoC disclosure impairs pay-for-performance evaluation and makes retention/trading pressure analysis difficult; monitor future proxies and any Item 5.02 filings for updates .
- Execution track record: During Wentworth’s tenure, TRDA transitioned to positive EBITDA and net income in FY 2024, with material revenue growth vs FY 2023 (see Performance table; values from S&P Global).*
- Risk flags: No CFO-specific pledging or related-party transactions disclosed; clawback policy in place. Absence of detailed CFO employment terms (non-compete, CoC) elevates uncertainty on retention economics in strategic transactions .